Gyre Therapeutics (GYRE) Other Non-Current Liabilities (2014 - 2026)

Gyre Therapeutics (GYRE) has reported Other Non-Current Liabilities for 7 consecutive years, with $2.9 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Non-Current Liabilities fell 15.85% year-over-year to $2.9 million; the TTM figure through Mar 2026 stood at $2.9 million (down 15.85% YoY), while the FY2025 annual figure was $1.4 million, down 74.45% from the prior year.
• Other Non-Current Liabilities climbed to $2.9 million in Q1 2026 per GYRE's latest filing, from $1.4 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $10.8 million in Q3 2024 and bottomed at $47000.0 in Q2 2024.
• Historically, Other Non-Current Liabilities has averaged $3.8 million across 4 years, with a median of $3.2 million in 2025.
• On a YoY basis, Other Non-Current Liabilities climbed as much as 11467.35% in 2024 and fell as far as 99.5% in 2024.
• Gyre Therapeutics' Other Non-Current Liabilities stood at $49000.0 in 2023, then soared by 11467.35% to $5.7 million in 2024, then slumped by 74.45% to $1.4 million in 2025, then surged by 98.34% to $2.9 million in 2026.
• Business Quant data shows GYRE's Other Non-Current Liabilities at $2.9 million in Q1 2026, $1.4 million in Q4 2025, and $3.2 million in Q3 2025.